Stockscreener 앱 받기
3.88
6.59%
0.24
시간 외 거래:
3.88
Rocket Pharmaceuticals Inc 주식(RCKT)의 최신 뉴스
Needham Maintains Rocket Pharmaceuticals(RCKT.US) With Hold Rating - Moomoo
Activity Recap: Is Rocket Pharmaceuticals Inc Equity Warrant a cyclical or defensive stock2026 News Drivers & Consistent Return Strategy Ideas - baoquankhu1.vn
Meme Stocks: Can Rocket Pharmaceuticals Inc expand into new markets2026 News Drivers & Stepwise Trade Execution Plans - baoquankhu1.vn
Big Picture: Will Rocket Pharmaceuticals Inc benefit from sector rotationQuarterly Portfolio Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
RCKT stock dives despite gene therapy approval — Wall Street dismisses sell-off - MSN
Volume Report: Can Rocket Pharmaceuticals Inc deliver consistent EPS growth2026 Stock Rankings & AI Forecast Swing Trade Picks - baoquankhu1.vn
Aug Ideas: Is Rocket Pharmaceuticals Inc exposed to political risk2026 Winners & Losers & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
RCKT Technical Analysis | Trend, Signals & Chart Patterns | ROCKET PHARMACEUTICALS INC (NASDAQ:RCKT) - ChartMill
[ARS] ROCKET PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Rocket Pharmaceuticals (NASDAQ: RCKT) seeks vote on director slate and option exchange - Stock Titan
Rally Mode: Is Rocket Pharmaceuticals Inc stock a good dividend stockPrice Action & Technical Confirmation Alerts - baoquankhu1.vn
US premarket movers: Argan, Rocket Pharmaceuticals, Unity - MSN
Rocket gene therapy, among FDA’s March approvals, earns PRV - biocentury.com
[SC TO-C] ROCKET PHARMACEUTICALS, INC. Tender Offer Communication | RCKT SEC FilingForm SC TO-C - Stock Titan
FDA Grants Accelerated Approval to Rocket Pharma’s Gene Therapy Kresladi for LAD-I - The Indian Practitioner
RCKTW SEC FilingsROCKET PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Rocket Pharmaceuticals Inc (9IP1.DU) valuation measures and financial statistics - Yahoo Finance UK
First Therapy Funded by California Taxpayer Dollars is Approved to Treat Rare Childhood Disorder - Noticias Newswire
Momentum Shift: What are Rocket Pharmaceuticals Incs growth levers2026 Action & Fast Entry High Yield Tips - baoquankhu1.vn
Rocket Pharmaceuticals, Inc. $RCKT Shares Acquired by JPMorgan Chase & Co. - MarketBeat
Why Rocket Pharmaceuticals (RCKT) got a commercial boost from FDA approval of KRESLADI - MSN
Aug Analyst Calls: Can Rocket Pharmaceuticals Inc expand into new markets2026 Market Overview & Verified Momentum Stock Alerts - baoquankhu1.vn
Rocket Pharmaceuticals Inc (9IP1.DU) Interactive Stock Chart - Yahoo! Finance Canada
RCKT: B of A Securities Raises Price Target on Buy Rating | RCKT Stock News - GuruFocus
Buyback Watch: Is Rocket Pharmaceuticals Inc Equity Warrant forming a breakout pattern2026 Setups & Accurate Technical Buy Alerts - baoquankhu1.vn
Risks Report: Is Rocket Pharmaceuticals Inc forming a bullish divergenceTrade Performance Summary & Growth-Oriented Investment Plans - baoquankhu1.vn
RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease - The Globe and Mail
Rocket Pharmaceuticals Files $400M Mixed Shelf Offering, Opens Financing Doors - timothysykes.com
Bank of America Forecasts Strong Price Appreciation for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock - MarketBeat
RCKT Shares Fall Even After FDA Approves Gene Therapy for Uncommon Disease - Bitget
Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI - Insider Monkey
FDA Approval Makes Rocket Pharma Gene Therapy the First for Ultra-Rare Immune Disorder - MedCity News
Rocket Pharmaceuticals (RCKT) Is Down 8.9% After FDA Accelerated Approval Of KRESLADI Gene Therapy - Yahoo Finance
Aug Analyst Calls: Whats the beta of Rocket Pharmaceuticals Inc Equity Warrant stock2026 Sector Review & Smart Money Movement Tracker - baoquankhu1.vn
Rocket Pharmaceuticals: Kresladi Approval Validates Platform, But Commercial Upside Remains Limited - Seeking Alpha
Rocket Pharma rises as FDA approves gene therapy - MSN
Assessing Rocket Pharmaceuticals (RCKT) Valuation After Accelerated FDA Approval Of KRESLADI - Sahm
Rocket Pharmaceuticals Delivers Bold Moves Amid Volatile Market - timothysykes.com
A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $9 to $16 - Moomoo
FDA approves Rocket Pharma’s Kresladi for severe LAD-I - thepharmaletter.com
Market movers: Unity, Rocket Pharma, Carnival Corp... - Proactive financial news
Rocket Pharmaceuticals Faces A Make-Or-Break FDA Call On KRESLADI - Finimize
BofA raises Rocket Pharmaceuticals price target on execution view By Investing.com - Investing.com Canada
Rocket Has Liftoff With Kresladi Approval, But Market Remains Small - insights.citeline.com
FDA approves Rocket’s Kresladi as first gene therapy for LAD-I - BioWorld MedTech
Rocket Pharmaceuticals (RCKT) Stock Pops on Historic FDA Gene Therapy Win - MEXC Exchange
Leerink raises Rocket Pharmaceuticals stock price target on FDA approval By Investing.com - Investing.com Canada
Rocket Pharmaceuticals (RCKT) Stock Surges After FDA Approves Groundbreaking Gene Therapy - MEXC
RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off - Stocktwits
2.69%
0.25%
자본화:
|
볼륨(24시간):